Table 2.

Association of CD24loCD38+CD27+ B-cell expansion with multiple myeloma activity

% pos on CD24loCD38+ PB B cellsSerum levels (mg/dL)% pos on CD24loCD38+CD27+ PB B cells
SubjectCD27KΛK/ΛIgGIgAIgMIgAIgMIgD
35.23.91.21.91,41058233.041.941.4
42.23.71.03.768861378.256.156.5
648.51.96670.01,1604,8009617.113.612.4
75.41.62.20.91,25052612120.232.436.1
86.17.30.612.13423,6901526.734.733.3
1032.7549.00.22,745.052824<639.99.77.0
1186.00.242.10.01,35024<634.728.514.9
1856.385.71.085.73,580202521.720.619.3
1968.098.10.2490.5397161018.230.325.2
204.730.32.512.19921,0602223.844.945.5
215.63.61.13.33,060823910.957.156.5
2578.241.61.921.91410281326.539.826.2
3233.299.00.6165709151919.38.327.8

NOTE: Displayed are light chain and immunoglobulin serum concentrations and the percentages of CD24loCD38+CD27+ B cells that expressed the indicated immunoglobulin. FACS data for each individual sample are shown in Supplementary Fig. S7. Serum K and Λ levels of the predominant light chain are printed in bold. Clinical data for each subject can be found in Table 1.